The $125 million offering more than doubles the company's cash position from $104.8 million to over $220 million, extending its runway into 2028. However, the massive dilution (25 million new shares vs. an estimated 37 million pre-offering shares outstanding) will pressure the stock. Watch for the Q4 2026 earnings report for updated cash runway guidance and clinical trial updates for PGN-EDODM1.
Drug in focus
PEPG drug pipeline →PGN-EDODM1
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
- Next catalyst
- None dated
What to watchWatch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $4.36entry
- T+1 · 20h ago −3.90%α −1.99% · $4.19
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PepGen entered into an underwriting agreement for a $125 million public offering of 25 million shares at $5.00 per share, with an option for underwriters to purchase an additional 3.75 million shares. The offering closed simultaneously with this 8-K filing, raising approximately $116.9 million in net proceeds (or $134.5 million if the option is fully exercised). The capital raise represents significant dilution, with the base offering alone adding roughly 73% to the company's pre-offering share count based on the $171 million market cap referenced in the cross-filing context.
Key Financial Metrics
Key Facts
- PepGen priced a public offering of 25,000,000 shares of common stock at $5.00 per share for gross proceeds of $125 million
- Underwriters have a 30-day option to purchase up to an additional 3,750,000 shares at the same price
- Net proceeds estimated at approximately $116.9 million, or $134.5 million if the option is fully exercised
- The offering was conducted as a takedown from an existing $400 million shelf registration statement (S-3) declared effective May 21, 2026
- Proceeds will fund ongoing clinical development of PGN-EDODM1, working capital and general corporate purposes
- The offering closed on the same day as this 8-K filing, with delivery expected on or about November 13, 2026
- The 424B5 filed on November 10, 2026 noted the company had $104.8 million cash on hand and a Q3 net loss of $19.4 million
Financial Impact
Gross proceeds of $125 million from 25 million shares at $5.00 per share; net proceeds of approximately $116.9 million. The offering size represents roughly 73% of the company's pre-offering market cap of $171 million.
Risk Factors
- Massive dilution: the base offering adds approximately 68% to the pre-offering share count, with the option adding another 10%
- The offering was executed at $5.00 per share, a 13% discount to the prior close of $4.61 on November 10, 2026
- As a clinical-stage biotech with no approved products, the company remains dependent on capital markets for funding
- The 60-day lock-up agreements with directors, officers and certain securityholders expire in January 2027, potentially adding selling pressure
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458597 |
| Document: d80190d8k.htm | 0001193125-26-458597 |
| Document: d80190dex51.htm | 0001193125-26-458597 |
| Document: d80190dex991.htm | 0001193125-26-458597 |
| Document: d80190dex992.htm | 0001193125-26-458597 |
| Document: 0001193125-26-458597-index-headers.html | 0001193125-26-458597 |
| Document: 0001193125-26-458597-index.html | 0001193125-26-458597 |
| Document: 0001193125-26-458597.txt | 0001193125-26-458597 |
Track record
12 reports on PEPG
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Viewing Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
- May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
- May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers